Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 101 full-time employees. The company went IPO on 2011-11-17. The firm has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Follow-Up Questions
Fortress Biotech Inc 'in CEO'su kimdir?
Dr. Adm. Lindsay Rosenwald 2009 'den beri şirketle birlikte olan Fortress Biotech Inc 'in Executive Chairman of the Board 'ıdır.
FBIOP hissesinin fiyat performansı nasıl?
FBIOP 'in mevcut fiyatı $9.01 'dir, son işlem günde 0.08% increased etti.
Fortress Biotech Inc için ana iş temaları veya sektörler nelerdir?
Fortress Biotech Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Fortress Biotech Inc 'in mevcut piyasa değerlemesi $268.2M 'dir
Fortress Biotech Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 6 analist Fortress Biotech Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 6 al, 1 tut, 0 sat ve 2 güçlü sat içermektedir
